368 related articles for article (PubMed ID: 26482878)
1. Poly(A)-specific ribonuclease (PARN) mediates 3'-end maturation of the telomerase RNA component.
Moon DH; Segal M; Boyraz B; Guinan E; Hofmann I; Cahan P; Tai AK; Agarwal S
Nat Genet; 2015 Dec; 47(12):1482-8. PubMed ID: 26482878
[TBL] [Abstract][Full Text] [Related]
2. Posttranscriptional manipulation of TERC reverses molecular hallmarks of telomere disease.
Boyraz B; Moon DH; Segal M; Muosieyiri MZ; Aykanat A; Tai AK; Cahan P; Agarwal S
J Clin Invest; 2016 Sep; 126(9):3377-82. PubMed ID: 27482890
[TBL] [Abstract][Full Text] [Related]
3. From incomplete penetrance with normal telomere length to severe disease and telomere shortening in a family with monoallelic and biallelic PARN pathogenic variants.
Dodson LM; Baldan A; Nissbeck M; Gunja SMR; Bonnen PE; Aubert G; Birchansky S; Virtanen A; Bertuch AA
Hum Mutat; 2019 Dec; 40(12):2414-2429. PubMed ID: 31448843
[TBL] [Abstract][Full Text] [Related]
4. Poly(A)-specific ribonuclease deficiency impacts telomere biology and causes dyskeratosis congenita.
Tummala H; Walne A; Collopy L; Cardoso S; de la Fuente J; Lawson S; Powell J; Cooper N; Foster A; Mohammed S; Plagnol V; Vulliamy T; Dokal I
J Clin Invest; 2015 May; 125(5):2151-60. PubMed ID: 25893599
[TBL] [Abstract][Full Text] [Related]
5. Chemical inhibition of PAPD5/7 rescues telomerase function and hematopoiesis in dyskeratosis congenita.
Shukla S; Jeong HC; Sturgeon CM; Parker R; Batista LFZ
Blood Adv; 2020 Jun; 4(12):2717-2722. PubMed ID: 32559291
[TBL] [Abstract][Full Text] [Related]
6. Telomere shortening and loss of self-renewal in dyskeratosis congenita induced pluripotent stem cells.
Batista LF; Pech MF; Zhong FL; Nguyen HN; Xie KT; Zaug AJ; Crary SM; Choi J; Sebastiano V; Cherry A; Giri N; Wernig M; Alter BP; Cech TR; Savage SA; Reijo Pera RA; Artandi SE
Nature; 2011 May; 474(7351):399-402. PubMed ID: 21602826
[TBL] [Abstract][Full Text] [Related]
7. Disruption of Telomerase RNA Maturation Kinetics Precipitates Disease.
Roake CM; Chen L; Chakravarthy AL; Ferrell JE; Raffa GD; Artandi SE
Mol Cell; 2019 May; 74(4):688-700.e3. PubMed ID: 30930056
[TBL] [Abstract][Full Text] [Related]
8. Small-Molecule PAPD5 Inhibitors Restore Telomerase Activity in Patient Stem Cells.
Nagpal N; Wang J; Zeng J; Lo E; Moon DH; Luk K; Braun RO; Burroughs LM; Keel SB; Reilly C; Lindsley RC; Wolfe SA; Tai AK; Cahan P; Bauer DE; Fong YW; Agarwal S
Cell Stem Cell; 2020 Jun; 26(6):896-909.e8. PubMed ID: 32320679
[TBL] [Abstract][Full Text] [Related]
9. Posttranscriptional modulation of TERC by PAPD5 inhibition rescues hematopoietic development in dyskeratosis congenita.
Fok WC; Shukla S; Vessoni AT; Brenner KA; Parker R; Sturgeon CM; Batista LFZ
Blood; 2019 Mar; 133(12):1308-1312. PubMed ID: 30728146
[TBL] [Abstract][Full Text] [Related]
10. The molecular genetics of the telomere biology disorders.
Bertuch AA
RNA Biol; 2016 Aug; 13(8):696-706. PubMed ID: 26400640
[TBL] [Abstract][Full Text] [Related]
11. Impaired telomere integrity and rRNA biogenesis in PARN-deficient patients and knock-out models.
Benyelles M; Episkopou H; O'Donohue MF; Kermasson L; Frange P; Poulain F; Burcu Belen F; Polat M; Bole-Feysot C; Langa-Vives F; Gleizes PE; de Villartay JP; Callebaut I; Decottignies A; Revy P
EMBO Mol Med; 2019 Jul; 11(7):e10201. PubMed ID: 31273937
[TBL] [Abstract][Full Text] [Related]
12. Regulation of poly(a)-specific ribonuclease activity by reversible lysine acetylation.
Dejene EA; Li Y; Showkatian Z; Ling H; Seto E
J Biol Chem; 2020 Jul; 295(30):10255-10270. PubMed ID: 32457045
[TBL] [Abstract][Full Text] [Related]
13. The effect of TERC haploinsufficiency on the inheritance of telomere length.
Goldman F; Bouarich R; Kulkarni S; Freeman S; Du HY; Harrington L; Mason PJ; Londoño-Vallejo A; Bessler M
Proc Natl Acad Sci U S A; 2005 Nov; 102(47):17119-24. PubMed ID: 16284252
[TBL] [Abstract][Full Text] [Related]
14. Disease anticipation is associated with progressive telomere shortening in families with dyskeratosis congenita due to mutations in TERC.
Vulliamy T; Marrone A; Szydlo R; Walne A; Mason PJ; Dokal I
Nat Genet; 2004 May; 36(5):447-9. PubMed ID: 15098033
[TBL] [Abstract][Full Text] [Related]
15. PARN Modulates Y RNA Stability and Its 3'-End Formation.
Shukla S; Parker R
Mol Cell Biol; 2017 Oct; 37(20):. PubMed ID: 28760775
[TBL] [Abstract][Full Text] [Related]
16. PARN and TOE1 Constitute a 3' End Maturation Module for Nuclear Non-coding RNAs.
Son A; Park JE; Kim VN
Cell Rep; 2018 Apr; 23(3):888-898. PubMed ID: 29669292
[TBL] [Abstract][Full Text] [Related]
17. Mutations in the telomerase component NHP2 cause the premature ageing syndrome dyskeratosis congenita.
Vulliamy T; Beswick R; Kirwan M; Marrone A; Digweed M; Walne A; Dokal I
Proc Natl Acad Sci U S A; 2008 Jun; 105(23):8073-8. PubMed ID: 18523010
[TBL] [Abstract][Full Text] [Related]
18. Functional characterization of novel telomerase RNA (TERC) mutations in patients with diverse clinical and pathological presentations.
Marrone A; Sokhal P; Walne A; Beswick R; Kirwan M; Killick S; Williams M; Marsh J; Vulliamy T; Dokal I
Haematologica; 2007 Aug; 92(8):1013-20. PubMed ID: 17640862
[TBL] [Abstract][Full Text] [Related]
19. TERT and TERC mutations detected in cryptic dyskeratosis congenita suppress telomerase activity.
Terada K; Miyake K; Yamaguchi H; Miyake N; Yamanaka K; Kojima S; Ito E; Inokuchi K; Okada T
Int J Lab Hematol; 2020 Jun; 42(3):316-321. PubMed ID: 32150348
[TBL] [Abstract][Full Text] [Related]
20. The RNase PARN Controls the Levels of Specific miRNAs that Contribute to p53 Regulation.
Shukla S; Bjerke GA; Muhlrad D; Yi R; Parker R
Mol Cell; 2019 Mar; 73(6):1204-1216.e4. PubMed ID: 30770239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
